CN115955971A - 盐酸米托蒽醌脂质体和环磷酰胺、长春新碱、强的松的用途 - Google Patents

盐酸米托蒽醌脂质体和环磷酰胺、长春新碱、强的松的用途 Download PDF

Info

Publication number
CN115955971A
CN115955971A CN202180052842.XA CN202180052842A CN115955971A CN 115955971 A CN115955971 A CN 115955971A CN 202180052842 A CN202180052842 A CN 202180052842A CN 115955971 A CN115955971 A CN 115955971A
Authority
CN
China
Prior art keywords
prednisone
vincristine
cyclophosphamide
mitoxantrone
ptcl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180052842.XA
Other languages
English (en)
Inventor
李春雷
夏雪芳
李彦辉
安娜
杜艳玲
李彤
王世霞
贾润露
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Shijiazhuang Pharma Group Zhongnuo Pharmaceutical Shijiazhuang Co Ltd
Original Assignee
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd filed Critical CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Publication of CN115955971A publication Critical patent/CN115955971A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

盐酸米托蒽醌脂质体和环磷酰胺、长春新碱、强的松在制备用于治疗外周T细胞淋巴瘤(PTCL)的药物中的用途。所述PTCL优选初治的PTCL。还可在上述基础上进一步使用其他治疗PTCL的一线、二线药物。一种治疗PTCL的方法，所述方法为给予患者治疗有效量的盐酸米托蒽醌脂质体和环磷酰胺、长春新碱及强的松。该药物的联合施用安全耐受，毒副作用小，并且能够在初治PTCL患者中获得较高的总客观缓解率(ORR)。

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN202180052842.XA 2020-08-27 2021-08-26 盐酸米托蒽醌脂质体和环磷酰胺、长春新碱、强的松的用途 Pending CN115955971A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010878461.4 2020-08-27
CN202010878461 2020-08-27
PCT/CN2021/114810 WO2022042653A1 (zh) 2020-08-27 2021-08-26 盐酸米托蒽醌脂质体和环磷酰胺、长春新碱、强的松的用途

Publications (1)

Publication Number Publication Date
CN115955971A true CN115955971A (zh) 2023-04-11

Family

ID=80352678

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180052842.XA Pending CN115955971A (zh) 2020-08-27 2021-08-26 盐酸米托蒽醌脂质体和环磷酰胺、长春新碱、强的松的用途

Country Status (8)

Country Link
US (1) US20240024257A1 (zh)
EP (1) EP4205747A1 (zh)
JP (1) JP2023539588A (zh)
KR (1) KR20230058137A (zh)
CN (1) CN115955971A (zh)
AU (1) AU2021334710A1 (zh)
CA (1) CA3190922A1 (zh)
WO (1) WO2022042653A1 (zh)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101209243B (zh) 2006-12-29 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 一种脂质体药物及其制备方法
CN110711178A (zh) * 2018-07-11 2020-01-21 石药集团中奇制药技术（石家庄）有限公司 盐酸米托蒽醌脂质体治疗非霍奇金淋巴瘤的用途

Also Published As

Publication number Publication date
EP4205747A1 (en) 2023-07-05
AU2021334710A1 (en) 2023-04-06
CA3190922A1 (en) 2022-03-03
WO2022042653A1 (zh) 2022-03-03
KR20230058137A (ko) 2023-05-02
JP2023539588A (ja) 2023-09-15
US20240024257A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
CN112384207B (zh) 米托蒽醌脂质体治疗非霍奇金淋巴瘤的用途
WO2022127760A1 (zh) 盐酸米托蒽醌脂质体的用途
CN115463118A (zh) 和厚朴酚在制备治疗或预防毛细血管瘤的药物中的用途
CN115087436A (zh) 盐酸米托蒽醌脂质体治疗乳腺癌的用途
US20020151508A1 (en) Methods for treating proliferative diseases
CN115955971A (zh) 盐酸米托蒽醌脂质体和环磷酰胺、长春新碱、强的松的用途
CN115427020A (zh) 盐酸米托蒽醌脂质体的用途
WO2021180184A1 (zh) 盐酸米托蒽醌脂质体的用途
WO2024017293A1 (zh) 盐酸米托蒽醌脂质体的用途
CN115770288A (zh) 米托蒽醌脂质体、硼替佐米和地塞米松治疗多发性骨髓瘤的用途
WO2024046246A1 (zh) 米托蒽醌脂质体联用卡培他滨治疗鼻咽癌的用途
CN115212168A (zh) 盐酸米托蒽醌脂质体的用途
CN115400083A (zh) 盐酸米托蒽醌脂质体用于制备治疗晚期实体瘤的药物的用途
WO2023207931A1 (zh) 米托蒽醌脂质体联合抗血管生成靶向药治疗卵巢癌的用途
WO2022028566A1 (zh) 盐酸米托蒽醌脂质体和培门冬酶的用途
WO2023174278A1 (zh) 抗tim-3抗体与去甲基化药物的药物组合
TW202346342A (zh) 抗tim-3抗體與抗pd-1抗體的藥物組合

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40084014

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20240408

Address after: 050035 No. 896, Zhongshan East Road, high tech Zone, Shijiazhuang City, Hebei Province

Applicant after: CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) Co.,Ltd.

Country or region after: China

Applicant after: CSPC ZHONGNUO PHARMACEUTICAL (SHIJIAZHUANG) Co.,Ltd.

Address before: 050035 No. 896, Zhongshan East Road, high tech Zone, Shijiazhuang City, Hebei Province

Applicant before: CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) Co.,Ltd.

Country or region before: China